Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Shots: The first patient has been dosed in the P-I ANTLER trial evaluating CB-010 in patients with r/r B-NHL. In the dose-escalation part of the study, patients who have failed at least 2L of CT or immunotherapy will receive the therapy following lymphodepletion The initial purpose of the dose escalation is to evaluate the safety […]